A copy of the complete text of the Company's
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Number Exhibit Description 10.1 Manufacturing Services Agreement, dated
August 16, 2013, by and between Navidea Biopharmaceuticals, Inc.and PETNET Solutions, Inc.(portions of this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the United States Securities and Exchange Commission). 99.1 Navidea Biopharmaceuticals, Inc.press release dated August 20, 2013, entitled " Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuanceof LymphoseekŪ Reimbursement Pass-Through C Code, Effective as of October 1, 2013." 99.2 Navidea Biopharmaceuticals, Inc.press release dated August 21, 2013, entitled "Navidea Biopharmaceuticals Signs Manufacturing Agreement with Siemens' PETNET Solutionsfor NAV4694 Beta-amyloid Imaging Agent." 99.3 Navidea Biopharmaceuticals, Inc.press release dated August 21, 2013, entitled "Navidea Awarded NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent Phase 3 Clinical Program Aimed at Alzheimer's Disease." 99.4 Navidea Biopharmaceuticals, Inc.press release dated August 22, 2013, entitled "Navidea Biopharmaceuticals Announces Agreement with FDAon Special Protocol Assessments for NAV5001 Phase 3 Program."
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements contained or incorporated by reference in this Current Report on Form 8-K, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the